Saudi Arabia vs Switzerland: Access to anti-retroviral drugs, female
Saudi Arabia
91.0%
in 2024
Switzerland
90.0%
in 2023
Saudi Arabia rank
25th
Switzerland rank
27th
Access to anti-retroviral drugs, female over time
- Saudi Arabia
- Switzerland
How they compare
Saudi Arabia currently reports 91.0% against 90.0% in Switzerland, a difference of 1.0%.
Across all 24 years both countries report, Switzerland has been ahead every year.
Saudi Arabia ranks 25th and Switzerland ranks 27th of 141 countries.
Switzerland has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Saudi Arabia | Switzerland | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 24.3% | 54.5% | 30.2% | Switzerland |
| 2010s | 62.5% | 83.6% | 21.1% | Switzerland |
| 2020s | 81.2% | 90.5% | 9.2% | Switzerland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Saudi Arabia or Switzerland?
- Saudi Arabia, at 91.0% against 90.0% in Switzerland as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Saudi Arabia and Switzerland?
- 1.0%, with Saudi Arabia ahead.
- How many years of comparable data are there for Saudi Arabia and Switzerland?
- 24 years are reported by both, from 2000 to 2023.
- How do Saudi Arabia and Switzerland rank globally for access to anti-retroviral drugs, female?
- Saudi Arabia ranks 25th and Switzerland ranks 27th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.